US Patent

US8129385 — Substituted 5-hydroxy-3,4,6,9,9a, 10-hexanhydro-2h-1-oxa04a,8a-diaza-anthracene-6,10-dioness

Composition of Matter · Assigned to Shionogi and Co Ltd · Expires 2027-10-05 · 1y remaining

Vulnerability score 17/100 Ironclad — strong claim type, well-established, deep family

What this patent protects

This patent protects a class of substituted 5-hydroxy-3,4,6,9,9a,10-hexahydro-2H-1-oxa-4a,8a-diaza-anthracene-6,10-diones useful as anti-HIV agents.

USPTO Abstract

The present invention is directed to a class of substituted 5-hydroxy-3,4,6,9,9a,10-hexahydro-2H-1-oxa-4a,8a-diaza-anthracene-6,10-diones useful as anti-HIV agents. The compounds have the formula: Z═O; R 20 , R 21 , R 22 , R 23 , R 24 and R 25 independently are hydrogen, C 1 -C 8 alkyl, (C 6 -C 14 )aryl-(C 1 -C 8 )alkyl, C 6 -C 14 aryl, or alkoxy; the stereochemistry of an asymmetric carbon represented by * shows R- or S-configuration, or a mixture thereof; R X is hydrogen; R 14 is hydrogen or optionally substituted lower alkyl; R 3 is hydrogen; R 1 is hydrogen or lower alkyl; R is halogen; and m is 1, 2 or 3; or a pharmaceutically acceptable salt thereof.

Drugs covered by this patent

Patent Metadata

Patent number
US8129385
Jurisdiction
US
Classification
Composition of Matter
Expires
2027-10-05
Drug substance claim
Yes
Drug product claim
Yes
Assignee
Shionogi and Co Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.